New study explores potential role of probiotics in Ehlers-Danlos Syndrome (EDS)

New research, believed to be the world’s largest study investigating the role of probiotics in Ehlers-Danlos Syndrome (EDS) has reported significant improvement in gastrointestinal symptoms, mental health and quality of life. The results were presented at the United European Gastroenterology (UEG) conference in Barcelona in October 2026.

Ehlers-Danlos Syndromes (EDS) are a group of genetic conditions that affect the body’s connective tissue, often causing unusually flexible joints and stretchy, fragile skin. As connective tissue is found throughout the body, EDS can cause a wide range of symptoms that are often less visible, making the condition difficult to diagnose and manage. In some cases, if the diagnostic criteria are not met, the individual is considered to have hypermobility spectrum disorder (HSD). For both EDS and HSD, gut symptoms are particularly common, alongside other conditions and symptoms such as chronic pain, anxiety and depression, postural orthostatic tachycardia syndrome (POTS) and mast cell activation syndrome (MCAS).

The 12-week, single-arm study of 274 people was conducted in collaboration with clinical experts at University College London Hospital and the charity, The EDS Support UK. The study explored the effects of Symprove, the liquid, multi-strain gut supplement, on gastrointestinal symptoms, mental health and quality of life for people with EDS/HSD using validated clinical questionnaires at baseline and after 6 and 12 weeks.

At the end of the study, 82% of people saw improvement in gastrointestinal symptoms, particularly indigestion, constipation and abdominal pain. Two thirds of people saw improvement in anxiety, including 22%  whose anxiety scores were in the normal range at the end of the study. Two thirds of people also saw improvement in depression, with 15%  scoring in the normal range at the end of the study.

Overall 63% of participants reported an improvement in quality of life. Improvements were seen  across all measures after six weeks, and the effect was maintained or improved further by end of the 12 week study.

Dr Asma Fikree, consultant gastroenterologist at University College London Hospital, said “People with EDS often struggle to find the right treatment plan to manage their varied symptoms, particularly for those that react to many treatments. These findings suggest Symprove can be an option to help address their gut symptoms while also supporting their mental health and quality of life”.

Nikki Casey, Head of Services at The EDS Support UK, said “We're delighted to have partnered with Symprove on this study, which adds to the growing evidence base around diet and lifestyle interventions for people living with EDS and HSD. The high completion rate (86%) and positive results show this is a real option for people in our community to consider as part of managing their symptoms and improving their quality of life. We hope these findings will encourage further research into practical interventions that could make a meaningful difference to the day-to-day lives of people living with EDS and HSD.”

Phil Thomas, Healthcare Professional Engagement Director at Symprove, said “We believe research should follow need, not numbers. People with EDS/HSD live with complex, often invisible health issues that can be challenging to manage so we partnered with The EDS Support UK to ensure this study captured what's important to the community. Hearing directly from them about what these results mean is exactly why we do this work.”

The study abstract presented at UEG is available on our Professionals website (Fikree A, et al. United European Gastroenterology Conference. 2026; Abstract 6724).
The full publication is in development ahead of submission to a peer-reviewed scientific journal.

About Symprove:

Symprove is the UK's No.1 live and active bacteria supplement*.

Founded in 1986 by Barry Smith, it was created to deliver good bacteria to the gut alive and active. Unlike many powder and capsule probiotics, Symprove's unique water-based formulation is designed to keep its four strains of live bacteria alive so they reach the gut ready to work**. 

The brand continues to invest in scientific research, with studies carried out at leading institutions including King's College Hospital, Sheffield Hallam and University College London.

For samples or more information, please get in touch with press@symprove.com.

* UK's No.1 live and active bacteria supplement. Source Euromonitor International Ltd; Consumer Health 2026ed., Symprove retail value sales, UK 2025 data.   
**Symprove’s friendly bacteria are proven to reach your gut alive and active based on a validated, in-vitro model (Simulator of the Human Intestinal Microbial  Ecosystem; SHIME®) showing 99.3% of bacteria remain viable in gut simulator conditions (Moens et al 2019).